From the Guidelines
Amniotic membrane transplantation was first used on human corneas in 1940 by ophthalmologist A.M. Sorsby. This technique has been used as a biological bandage for treating ocular surface disorders, specifically to manage chemical burns of the eye. The procedure involves placing processed human amniotic membrane onto the corneal surface to promote healing. This membrane is particularly effective because it contains growth factors, anti-inflammatory proteins, and anti-scarring properties that support corneal epithelial growth while reducing inflammation and preventing excessive scarring 1. The use of amniotic membrane transplantation has evolved over time, with various techniques being developed, including the "inlay" and "overlay" methods, as well as the use of self-retaining amniotic membranes 1. Today, amniotic membrane transplantation is widely used to treat various corneal conditions, including persistent epithelial defects, corneal ulcers, chemical burns, and after certain surgical procedures to promote healing 1. Some of the key benefits of amniotic membrane transplantation include its ability to promote healing, reduce inflammation, and prevent excessive scarring. The technique has undergone significant advancements in recent years, with improved preservation methods making the tissue more readily available for ophthalmic use. Key considerations for the use of amniotic membrane transplantation include the selection of appropriate candidates, the choice of technique, and the management of potential complications. Overall, amniotic membrane transplantation is a valuable treatment option for a range of corneal conditions, offering a number of benefits and advantages over other treatments. The most recent evidence suggests that amniotic membrane transplantation is a safe and effective treatment for promoting corneal healing and reducing the risk of complications 1. In terms of specific applications, amniotic membrane transplantation has been used to treat a range of conditions, including corneal edema and opacification, as well as to promote healing after surgical procedures. The use of amniotic membrane transplantation has also been shown to be effective in reducing the development of scar tissue and promoting epithelial growth. Overall, the evidence suggests that amniotic membrane transplantation is a valuable treatment option for a range of corneal conditions, and its use is supported by a growing body of evidence 1.
From the Research
Amniotic Membrane Transplantation on Human Corneas
- The exact date of the first amniotic membrane transplantation on human corneas is not specified in the provided studies.
- However, the use of amniotic membrane transplantation in ophthalmology has been reported in various studies, including its application in ocular surface disorders 2.
- One of the earliest reported uses of amniotic membrane transplantation was by deRoth for conjunctival surface reconstruction, but the specific year is not mentioned in the provided studies 2.
- The provided studies discuss the use of amniotic membrane transplantation in various ocular surface disorders, including corneal ulcers, bullous keratopathy, and persistent epithelial defects 3, 4, 5, 6.
- These studies demonstrate the effectiveness of amniotic membrane transplantation in promoting epithelialization, reducing inflammation, and improving visual acuity in patients with ocular surface disorders 3, 4, 5, 6.